A study based at Johns Hopkins University is comparing two treatment strategies in 900 people newly diagnosed with relapsing-remitting MS, or with onset/diagnosis of relapsing-remitting MS in the past who have received minimal or no treatment. The study is recruiting at approximately 45 centers nationwide. One option is an escalation approach, in which people start taking a less powerful therapy with the option of switching to a more potent therapy if disease activity continues. The other approach involves starting with a stronger therapy that is potentially more effective, but also carries the potential for greater risk for significant adverse effects. The “Traditional versus Early Aggressive Therapy for Multiple Sclerosis” (TREAT-MS) Trial is funded by the Patient-Centered Outcomes Research Institute (PCORI).